NEW YORK – Human Longevity said on Wednesday that it has raised $39.8 million in a second Series B financing round.
TVM Capital Healthcare led the round, joined by Panacea Venture and Emerging Technology Partners.
In a statement, HLI said it would use the funding to invest in its health risk and recommendation platform, new technologies and services focused on longevity, and to expand globally including in Europe, Asia, and Saudi Arabia.
HLI has now raised over $369.8 million since its founding in 2013 by Craig Venter, former CEO of Celera and a leading figure in the race to sequence the human genome at the turn of the millennium. Venter left HLI in 2017; shortly thereafter, the firm sued him, alleging theft of trade secrets, a case that was dismissed. According to HLI's website, Venter is currently its Chief Scientific Advisor.
HLI raised $220 million in its initial Series B funding round in 2016 and $80 million in Series A funding in 2014. It secured an additional $30 million in 2019.
In 2022, HLI announced it would go public through a special-purpose acquisition company; however, the deal appears not to have been completed. The company did not immediately respond to a request for comment on the SPAC deal.